Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

被引：0

作者：

Costa, Luciano ^{[1
]}

Bar, Noffar ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
]}

Paris, Laura ^{[6
]}

Hofmeister, Craig ^{[7
]}

Rodriguez-Otero, Paula

Bermudez, Maria Aranzazu ^{[9
]}

Santoro, Armando ^{[8
,10
]}

Yee, Andrew ^{[11
]}

Creignou, Maria ^{[12
]}

Encinas, Cristina ^{[13
]}

Cerchione, Claudio ^{[14
]}

de la Rubia, Javier ^{[15
]}

Oriol, Albert ^{[16
]}

Ferstl, Barbara ^{[17
]}

Besemer, Britta ^{[18
]}

Chen, Jinjie ^{[19
]}

Boss, Isaac ^{[19
]}

Gaudy, Allison ^{[19
]}

Hsu, Kevin ^{[19
]}

Godwin, Colin ^{[19
]}

San-Miguel, Jesus ^{[20
]}

Wong, Sandy ^{[21
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] ASST Papa Giovanni XXIII, Bergamo, Italy

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[9] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[10] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Hosp Gen Univ Gregorio Maranon HGUGM, IiSGM, Madrid, Spain

[14] Ist Scientif Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[15] Univ Hosp La Fe, Dept Hematol, Valencia, Spain

[16] Hosp Germans Trias i Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain

[17] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[18] Univ Tubingen Hosp, Tubingen, Germany

[19] Bristol Myers Squibb, Princeton, NJ USA

[20] Inst Invest Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc, Canc Ctr Clin Univ Navarra, Pamplona, Spain

[21] Univ Calif San Francisco, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-033

引用

页码：S52 / S53

页数：2

共 50 条

[41] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
[42] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Cohen, Yael C.
Morillo, Daniel
Gatt, Moshe E.
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Oriol, Albert
Ocio, Enrique M.
Yoon, Sung-Soo
Mateos, Maria-Victoria
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Guo, Yue
Krevvata, Maria
Peterson, Michelle R.
Beelen, Melissa Jo
Vanak, Jill
Banerjee, Arnob
Magen, Hila
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Magen, Hila
Morillo, Daniel
Gatt, Moshe
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Oriol, Albert
Ocio, Enrique
Yoon, Sung-Soo
Mateos, Maria-Victoria
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Guo, Yue
Krevvata, Maria
Peterson, Michelle
Beelen, Melissa
Vanak, Jill
Banerjee, Arnob
Cohen, Yael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S50
[45] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Chari, Ajai
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez, Paula
Askari, Elham
Mateos, Maria-Victoria
Minnema, Monique C.
Verona, Raluca
Girgis, Suzette
Prior, Thomas
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Krishnan, Amrita
BLOOD, 2020, 136
[46] Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study
Vogl, Dan T.
Kaufman, Jonathan L.
Holstein, Sarah A.
Atrash, Shebli
Nadeem, Omar
Janakiram, Murali
Suryanarayan, Kaveri
Liu, Yuyin
Collins, Sabrina
Parot, Xavier
Chaudhry, Maria
BLOOD, 2021, 138
[47] Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
Spencer, Andrew
Iversen, Katrine Fladeland
Dhakal, Binod
Creignou, Maria
Chen, Jenny
Hiemstra, Ida H.
Bosgra, Sieto
Badani, Avani
Breij, Esther C. W.
Brady, Lauren K.
Sasser, A. Kate
Malmberg, Anders
Gregersen, Henrik
Hansson, Markus
Broijl, Annemiek
Mateos, Maria-Victoria
Plesner, Torben
BLOOD, 2022, 140 : 7320 - 7321
[48] Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy
Dholaria, Bhagirathbhai
Shune, Leyla
Kin, Andrew
McArthur, Katherine
Eskew, Jeff D.
Martin, Christopher E.
Haag, Sabrina
McCaigue, Joanne
Namini, Hamid
DePrimo, Sam
Cranert, Stacey
Coronella, Julia
Shedlock, Devon
Belani, Rajesh
CANCER RESEARCH, 2024, 84 (07)
[49] Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Krishnan, Amrita Y.
Minnema, Monique C.
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Askari, Elham
Mateos, Maria-Victoria
Costa, Luciano J.
Verona, Raluca I.
Ma, Xuewen
Girgis, Suzette
Yang, Shiyi
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Chari, Ajai
BLOOD, 2021, 138
[50] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Popat, Rakesh
Usmani, Saad Z.
Garfall, Alfred
van de Donk, Niels
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Chari, Ajai
Karlin, Lionel
Benboubker, Lotfi
Mateos, Maria-Victoria
Bahlis, Nizar
Moreau, Philippe
Besemer, Britta
Martinez-Lopez, Joaquin
Sidana, Surbhi
Pei, Lixia
Trancucci, Danielle
Verona, Raluca
Girgis, Suzette
Olyslager, Yunsi
Jaffe, Mindy
Uhlar, Clarissa
Stephenson, Tara
Van Rampelbergh, Rian
Banerjee, Arnob
Goldberg, Jenna D.
Kobos, Rachel
Krishnan, Amrita
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36

← 1 2 3 4 5 →